Safety and feasibility
nausea, fatigue, thrombocytopenia, vomiting, anemia, anorexia
ADVERSE EVENTS, THROMBOCYTOPENIA, ANOREXIA, ANEMIA
nAde was not associated with any previously unreported toxic effects or severe adverse events (grade 3 or more). Treatment-related adverse events of any grade occurred in 14 of 25 patients (56%); most treatment-related adverse events were mild (grade 1). Common adverse events related to nAde were anorexia (eight patients, 32%), fatigue (four patients, 16%), thrombocytopenia (three patients, 12%), nausea (three patients, 12%), vomiting (two patients, 8%) and anemia (one patient, 4%) (Extended Data Table 